恢复期血浆治疗与ICU收治的COVID-19患者死亡率:一项前瞻性观察性研究
本研究为单中心前瞻性观察性队列研究,纳入120例因COVID-19相关急性呼吸衰竭入住ICU的患者,其中48例接受恢复期血浆(CVP)治疗,采用倾向性评分逆概率治疗加权(IPTW)分析校正组间预后变量失衡。结果显示30天ICU总生存率CVP组为69%,非CVP组为54%(log-rank p=0.049),IPTW加权后CVP与总生存的有利关联更强(log-rank p=0.035)。探索性分析显示,在接受无创通气的患者中,CVP治疗与总生存获益相关(HR 0.12,95%CI 0.03-0.57,p=0.007)。作者结论认为,在COVID-19相关急性呼吸衰竭患者中给予CVP与ICU生存率改善相关。
要点
- 单中心前瞻性观察性队列纳入120例COVID-19急性呼吸衰竭ICU患者,48例接受恢复期血浆(CVP)治疗。
- 30天ICU总生存率CVP组69% vs 非CVP组54%(log-rank p=0.049)。
- IPTW加权后CVP与总生存的有利关联更强(log-rank p=0.035)。
- 探索性分析:无创通气患者接受CVP与总生存获益相关(HR 0.12,95%CI 0.03-0.57,p=0.007)。
- 所有患者均需某种通气支持,52%接受有创通气,中位PaO2/FiO2(Horowitz指数)92 [77-150]。
适用人群与场景
- 因COVID-19相关急性呼吸衰竭入住ICU的成人患者;中位年龄66岁(25th-75th百分位54-75),女性占30%。
- 所有患者均需要某种通气支持,其中52%接受有创通气;88%表现为严重急性呼吸衰竭,中位PaO2/FiO2(Horowitz指数)为92 [77-150]。
诊断标准与关键阈值
- 入住ICU后立即根据预先设定的标准将患者分配至CVP治疗,以快速识别可能适合该治疗的患者。
处置流程与药物剂量
- 入住ICU后立即根据预先设定的标准分配至CVP治疗组(48例)或非CVP组(72例)。
研究设计与关键结果
- 研究类型:单中心前瞻性观察性队列研究;样本量120例,其中48例接受CVP治疗。
- 主要终点:30天ICU总生存率CVP组69% vs 非CVP组54%(log-rank p=0.049)。
- IPTW加权后,CVP与总生存的有利关联更强(log-rank p=0.035)。
- 探索性分析:无创通气患者中CVP治疗与总生存获益相关(HR 0.12,95%CI 0.03-0.57,p=0.007)。
证据类型、等级与局限
- 证据类型:单中心前瞻性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在COVID-19相关急性呼吸衰竭患者中给予CVP与ICU生存率改善相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: This study aimed to quantify the potential survival benefit of convalescent plasma therapy (CVP) in critically ill patients with acute respiratory failure related to coronavirus disease-2019 (COVID-19).
METHODS: This is a single-center prospective observational cohort study in COVID-19 patients with acute respiratory failure. Immediately after intensive care unit (ICU) admission patients were allocated to CVP treatment following pre-specified criteria to rapidly identify those patients potentially susceptible for this treatment. A propensity score adjustment [inverse probability of treatment weighted (IPTW) analysis] was implemented to account rigorously for imbalances in prognostic variables between the treatment groups.
RESULTS: We included 120 patients of whom 48 received CVP. Thirty percent were female with a median age of 66 years [25th-75th percentile 54-75]. Eighty-eight percent of patients presented with severe acute respiratory failure as displayed by a median paO2/FiO2 ratio (Horowitz Index) of 92 [77-150]. All patients required any kind of ventilatory support with more than half of them (52%) receiving invasive ventilation. Thirty-day ICU overall survival (OS) was 69% in the CVP group and 54% in the non-CVP group (log-rank p = 0.049), respectively. After weighing the time-to-event data for the IPTW, the favorable association between CVP and OS became even stronger (log-rank p = 0.035). Moreover, an exploratory analysis showed an overall survival benefit of CVP therapy for patients with non-invasive ventilation (Hazard ratio 0.12 95% CI 0.03-0.57, p = 0.007) CONCLUSION: Administration of CVP in patients with acute respiratory failure related to COVID-19 is associated with improved ICU survival rates.
参考来源
- Hatzl S, Posch F, Sareban N, et al. Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study. Ann Intensive Care. 2021. PMID: 33978844. doi:10.1186/s13613-021-00867-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。